(0.02%) 5 522.50 points
(0.15%) 39 529 points
(-0.07%) 19 913 points
(0.40%) $81.87
(-1.00%) $2.58
(-0.06%) $2 338.20
(0.93%) $29.51
(-0.40%) $997.90
(-0.48%) $0.929
(-0.54%) $10.62
(-0.23%) $0.789
(1.49%) $87.00
Live Chart Being Loaded With Signals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases...
Stats | |
---|---|
Dagens volum | 71 150 |
Gjennomsnittsvolum | 2.21M |
Markedsverdi | 190.84B |
EPS | £1.410 ( Q1 | 2024-03-31 ) |
Neste inntjeningsdato | ( £1.530 ) 2024-07-24 |
Last Dividend | £123.25 ( 2024-02-22 ) |
Next Dividend | £0 ( N/A ) |
P/E |
38.47 (Sector) 0 (Industry) 0 |
ATR14 | £4.69 (0.04%) |
Volum Korrelasjon
AstraZeneca PLC Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
AstraZeneca PLC Korrelasjon - Valuta/Råvare
AstraZeneca PLC Økonomi
Annual | 2023 |
Omsetning: | £45.81B |
Bruttogevinst: | £37.54B (81.95 %) |
EPS: | £3.84 |
FY | 2023 |
Omsetning: | £45.81B |
Bruttogevinst: | £37.54B (81.95 %) |
EPS: | £3.84 |
FY | 2022 |
Omsetning: | £44.35B |
Bruttogevinst: | £31.96B (72.06 %) |
EPS: | £2.12 |
FY | 2021 |
Omsetning: | £37.42B |
Bruttogevinst: | £24.98B (66.76 %) |
EPS: | £0.0854 |
Financial Reports:
No articles found.
AstraZeneca PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£62.90 (N/A) |
£0 (N/A) |
£135.30 (N/A) |
£0 (N/A) |
£56.54 (N/A) |
£0 (N/A) |
£123.25 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £6.94 | 1993-09-20 |
Last Dividend | £123.25 | 2024-02-22 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 62 | -- |
Total Paid Out | £2 628.66 | -- |
Avg. Dividend % Per Year | 1.63% | -- |
Score | 4.95 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.81 | |
Div. Directional Score | 8.91 | -- |
Year | Amount | Yield |
---|---|---|
1993 | £0 | 0.00% |
1994 | £0 | 0.00% |
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £0 | 0.00% |
2019 | £170.15 | 2.79% |
2020 | £166.98 | 2.18% |
2021 | £144.82 | 1.95% |
2022 | £170.91 | 2.02% |
2023 | £191.84 | 1.66% |
2024 | £123.25 | 1.14% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
22 Feb 2024 | £123.25 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
10 Aug 2023 | £56.54 | 30 Nov -0001 | 11 Aug 2023 | 11 Sep 2023 |
23 Feb 2023 | £135.30 | 09 Feb 2023 | 24 Feb 2023 | 27 Mar 2023 |
11 Aug 2022 | £62.90 | 29 Jul 2022 | 12 Aug 2022 | 12 Sep 2022 |
24 Feb 2022 | £108.01 | 10 Feb 2022 | 25 Feb 2022 | 28 Mar 2022 |
12 Aug 2021 | £46.82 | 29 Jul 2021 | 13 Aug 2021 | 13 Sep 2021 |
25 Feb 2021 | £98.00 | 11 Feb 2021 | 26 Feb 2021 | 29 Mar 2021 |
13 Aug 2020 | £53.26 | 24 Oct 2019 | 14 Aug 2020 | 14 Sep 2020 |
27 Feb 2020 | £113.72 | 24 Oct 2019 | 28 Feb 2020 | 30 Mar 2020 |
08 Aug 2019 | £59.33 | 08 Nov 2018 | 09 Aug 2019 | 09 Sep 2019 |
28 Feb 2019 | £110.82 | 08 Nov 2018 | 01 Mar 2019 | 27 Mar 2019 |
09 Aug 2018 | £53.29 | 09 Nov 2017 | 10 Aug 2018 | 10 Sep 2018 |
15 Feb 2018 | £95.28 | 09 Nov 2017 | 16 Feb 2018 | 19 Mar 2018 |
10 Aug 2017 | £53.05 | 02 Feb 2017 | 11 Aug 2017 | 11 Sep 2017 |
16 Feb 2017 | £120.51 | 16 Nov 2016 | 17 Feb 2017 | 20 Mar 2017 |
11 Aug 2016 | £53.03 | 04 Feb 2016 | 12 Aug 2016 | 12 Sep 2016 |
18 Feb 2016 | £91.59 | 04 Feb 2016 | 19 Feb 2016 | 21 Mar 2016 |
13 Aug 2015 | £36.84 | 30 Jul 2015 | 14 Aug 2015 | 14 Sep 2015 |
19 Feb 2015 | £81.07 | 06 Nov 2014 | 20 Feb 2015 | 23 Mar 2015 |
13 Aug 2014 | £31.76 | 31 Jul 2014 | 15 Aug 2014 | 15 Sep 2014 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
DNA2.L | Dividend Royal | 2024-04-18 | Quarterly | 9 | 16.51% | 8.69 |
MPLS.L | Dividend Royal | 2024-04-11 | Quarterly | 7 | 12.84% | 8.67 |
FAIR.L | Dividend Royal | 2024-05-30 | Quarterly | 9 | 10.77% | 8.67 |
BGLF.L | Dividend Royal | 2024-05-02 | Quarterly | 9 | 10.03% | 8.50 |
SEPL.L | Dividend Royal | 2024-05-30 | Quarterly | 11 | 10.34% | 8.34 |
DNA3.L | Dividend Royal | 2024-04-18 | Quarterly | 12 | 14.16% | 8.31 |
DEC.L | Dividend Royal | 2024-08-29 | Quarterly | 8 | 59.83% | 7.91 |
AA4.L | Dividend Royal | 2024-04-11 | Quarterly | 9 | 12.37% | 7.88 |
IMB.L | Dividend Royal | 2024-08-22 | Quarterly | 28 | 7.10% | 7.51 |
FBH.L | Dividend Royal | 2024-05-02 | Annually | 22 | 11.26% | 7.46 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.133 | 1.500 | 7.34 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0619 | 1.200 | 7.94 | 9.52 | [0 - 0.3] |
returnOnEquityTTM | 0.168 | 1.500 | 9.25 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.706 | -1.000 | 2.94 | -2.94 | [0 - 1] |
currentRatioTTM | 0.886 | 0.800 | -0.572 | -0.458 | [1 - 3] |
quickRatioTTM | 0.661 | 0.800 | -0.820 | -0.656 | [0.8 - 2.5] |
cashRatioTTM | 0.271 | 1.500 | 9.60 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.338 | -1.500 | 4.37 | -6.56 | [0 - 0.6] |
interestCoverageTTM | 5.33 | 1.000 | 9.14 | 9.14 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.26 | 2.00 | 7.91 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.73 | 2.00 | 8.13 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.923 | -1.500 | 6.31 | -9.46 | [0 - 2.5] |
grossProfitMarginTTM | 0.820 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.184 | 1.000 | 8.32 | 8.32 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.281 | 1.000 | 9.55 | 9.55 | [0.2 - 2] |
assetTurnoverTTM | 0.465 | 0.800 | -0.230 | -0.184 | [0.5 - 2] |
Total Score | 11.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 38.27 | 1.000 | 6.24 | 0 | [1 - 100] |
returnOnEquityTTM | 0.168 | 2.50 | 9.52 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.73 | 2.00 | 8.76 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.149 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.26 | 2.00 | 7.91 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.706 | 1.500 | 2.94 | -2.94 | [0 - 1] |
pegRatioTTM | 168.99 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.204 | 1.000 | 7.41 | 0 | [0.1 - 0.5] |
Total Score | 6.81 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.